Find Deuruxolitinib phosphate manufacturers, exporters & distributors on PharmaCompass

PharmaCompass

Synopsis

Synopsis

ACTIVE PHARMA INGREDIENTS

0

USDMF

US DMFs Filed

0

CEP/COS

CEP/COS Certifications

0

JDMF

JDMFs Filed

0

EU WC

EU WC

0

KDMF

KDMF

0

NDC API

NDC API

0

VMF

NDC API

0INTERMEDIATES

REF. STANDARDS OR IMPURITIES

0

EDQM

0

USP

0

JP

0

Others

FINISHED DOSAGE FORMULATIONS

0

Europe

Europe

0

Canada

Canada

0

Australia

Australia

0

South Africa

South Africa

0

Listed Dossiers

Listed Dossiers

FDF Dossiers

DRUG PRODUCT COMPOSITIONS

0RELATED EXCIPIENT COMPANIES

0EXCIPIENTS BY APPLICATIONS

PATENTS & EXCLUSIVITIES

0

Health Canada Patents

API REF. PRICE (USD/KG)

$
$ 0

GLOBAL SALES INFORMATION

US Medicaid

NA

Annual Reports

NA

Regulatory FDF Prices

NA

API/FDF Prices: Book a Demo to
explore the features and consider
upgrading later

MARKET PLACE

0

API

0

FDF

DIGITAL CONTENT

0

Stock Recap #PipelineProspector

0

Weekly News Recap #Phispers

Chemistry

Click the arrow to open the dropdown
read-moreClick the button for full data set
Also known as: Ctp-543 phosphate, C-21543 phosphate, D8-ruxolitinib phosphate, D8- ruxolitinib phosphate, 8vj43s4lcm, Deuruxolitinib phosphate [usan]
Molecular Formula
C17H21N6O4P
Molecular Weight
412.4  g/mol
InChI Key
JFMWPOCYMYGEDM-NTVOUFPTSA-N
FDA UNII
8VJ43S4LCM

Deuruxolitinib phosphate
1 2D Structure

Deuruxolitinib phosphate

2 Identification
2.1 Computed Descriptors
2.1.1 IUPAC Name
(3R)-3-(2,2,3,3,4,4,5,5-octadeuteriocyclopentyl)-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)pyrazol-1-yl]propanenitrile;phosphoric acid
2.1.2 InChI
InChI=1S/C17H18N6.H3O4P/c18-7-5-15(12-3-1-2-4-12)23-10-13(9-22-23)16-14-6-8-19-17(14)21-11-20-16;1-5(2,3)4/h6,8-12,15H,1-5H2,(H,19,20,21);(H3,1,2,3,4)/t15-;/m1./s1/i1D2,2D2,3D2,4D2;
2.1.3 InChI Key
JFMWPOCYMYGEDM-NTVOUFPTSA-N
2.1.4 Canonical SMILES
C1CCC(C1)C(CC#N)N2C=C(C=N2)C3=C4C=CNC4=NC=N3.OP(=O)(O)O
2.1.5 Isomeric SMILES
[2H]C1(C(C(C(C1([2H])[2H])([2H])[2H])([2H])[2H])[C@@H](CC#N)N2C=C(C=N2)C3=C4C=CNC4=NC=N3)[2H].OP(=O)(O)O
2.2 Other Identifiers
2.2.1 UNII
8VJ43S4LCM
2.3 Synonyms
2.3.1 Depositor-Supplied Synonyms

1. Ctp-543 Phosphate

2. C-21543 Phosphate

3. D8-ruxolitinib Phosphate

4. D8- Ruxolitinib Phosphate

5. 8vj43s4lcm

6. Deuruxolitinib Phosphate [usan]

7. 2147706-60-1

8. Deuruxolitinib Phosphate (usan)

9. (3r)-3-(2,2,3,3,4,4,5,5-d8)cyclopentyl-3-(4-(7h-pyrrolo(2,3-d)pyrimidin-4-yl)-1h-pyrazol-1-yl)propanenitrile Phosphate (1:1)

10. Leqselvi (tn)

11. Unii-8vj43s4lcm

12. Chembl4594382

13. D11867

14. 1h-pyrazole-1-propanenitrile, .beta.-(cyclopentyl-2,2,3,3,4,4,5,5-d8)-4-(7h-pyrrolo(2,3-d)pyrimidin-4-yl)-, (.beta.r)-, Phosphate

15. 1h-pyrazole-1-propanenitrile, Beta-(cyclopentyl-2,2,3,3,4,4,5,5-d8)-4-(7hpyrrolo(2,3-d)pyrimidin-4-yl)-, (betar)-, Phosphate (1:1)

2.4 Create Date
2020-08-20
3 Chemical and Physical Properties
Molecular Weight 412.4 g/mol
Molecular Formula C17H21N6O4P
Hydrogen Bond Donor Count4
Hydrogen Bond Acceptor Count8
Rotatable Bond Count4
Exact Mass g/mol
Monoisotopic Mass g/mol
Topological Polar Surface Area161
Heavy Atom Count28
Formal Charge0
Complexity503
Isotope Atom Count8
Defined Atom Stereocenter Count1
Undefined Atom Stereocenter Count0
Defined Bond Stereocenter Count0
Undefined Bond Stereocenter Count0
Covalently Bonded Unit Count2

API SUPPLIERS

read-more
read-more

01

MSN Laboratories

India

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

American Thoracic Society
Not Confirmed
arrow
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

Listed Suppliers

read-more
read-more

01

Hospitalar
Not Confirmed
arrow
arrow
Hospitalar
Not Confirmed

Deuruxolitinib

About the Company : Founded in 2003, Hyderabad-based MSN Labs is one of the fastest-growing research-based pharmaceutical company in India. Boasting a diverse product portfolio, with multiple products...

Founded in 2003, Hyderabad-based MSN Labs is one of the fastest-growing research-based pharmaceutical company in India. Boasting a diverse product portfolio, with multiple products in the market and in the pipeline, MSN has 6 API (including Oncology) and one finished dosage facilities (one more for Oncology is being built) and an integrated R&D Center for Contract Research And Manufacturing Services (CRAMS) located in Hyderabad. MSN has won the trust of more than 250 customers across 65 countries around the globe covering the US, Europe, Latin America, Middle-East, Asia Pacific, Africa and CIS markets. Our product basket offers 100 APIs
blank
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

Drugs in Development

read-more
read-more

Details:

Leqselvi (deuruxolitinib phosphate) is a JAK1/JAK2 inhibitor, small molecule drug candidate, which is being evaluated for the treatment of severe alopecia areata in adults.


Lead Product(s): Deuruxolitinib phosphate

Therapeutic Area: Dermatology Brand Name: Leqselvi

Study Phase: Approved FDFProduct Type: Other Small Molecule

Sponsor: Inapplicable

Deal Size: Inapplicable Upfront Cash: Inapplicable

Deal Type: Inapplicable July 26, 2024

blank

01

Hospitalar
Not Confirmed
Hospitalar
Not Confirmed

Details : Leqselvi (deuruxolitinib phosphate) is a JAK1/JAK2 inhibitor, small molecule drug candidate, which is being evaluated for the treatment of severe alopecia areata in adults.

Product Name : Leqselvi

Product Type : Other Small Molecule

Upfront Cash : Inapplicable

July 26, 2024

blank

Details:

CTP-543 (deuruxolitinib) is an investigational oral selective inhibitor of Janus kinases JAK1 and JAK2, which is investigated for the treatmet of moderate to severe alopecia areata.


Lead Product(s): Deuruxolitinib phosphate

Therapeutic Area: Dermatology Brand Name: Leqselvi

Study Phase: Phase IIIProduct Type: Other Small Molecule

Sponsor: Inapplicable

Deal Size: Inapplicable Upfront Cash: Inapplicable

Deal Type: Inapplicable June 10, 2023

blank

02

Hospitalar
Not Confirmed
Hospitalar
Not Confirmed

Details : CTP-543 (deuruxolitinib) is an investigational oral selective inhibitor of Janus kinases JAK1 and JAK2, which is investigated for the treatmet of moderate to severe alopecia areata.

Product Name : Leqselvi

Product Type : Other Small Molecule

Upfront Cash : Inapplicable

June 10, 2023

blank

Details:

Acquisition adds CTP‑543 (deuruxolitinib), a Potential Best-in-Class oral inhibitor of Janus kinases JAK1 and JAK2 for the treatment of Alopecia Areata, an autoimmune dermatological disease which is in late-stage development, to Sun Pharma's Global Dermatology Portfolio.


Lead Product(s): Deuruxolitinib phosphate

Therapeutic Area: Dermatology Brand Name: CTP-543

Study Phase: Phase IIIProduct Type: Other Small Molecule

Sponsor: Sun Pharmaceutical Industries Limited

Deal Size: $576.0 million Upfront Cash: $576.0 million

Deal Type: Acquisition June 03, 2023

blank

03

Hospitalar
Not Confirmed
Hospitalar
Not Confirmed

Lead Product(s) : Deuruxolitinib phosphate

Therapeutic Area : Dermatology

Highest Development Status : Phase III

Partner/Sponsor/Collaborator : Sun Pharmaceutical Industries Limited

Deal Size : $576.0 million

Deal Type : Acquisition

Details : Acquisition adds CTP‑543 (deuruxolitinib), a Potential Best-in-Class oral inhibitor of Janus kinases JAK1 and JAK2 for the treatment of Alopecia Areata, an autoimmune dermatological disease which is in late-stage development, to Sun Pharma's Global Der...

Product Name : CTP-543

Product Type : Other Small Molecule

Upfront Cash : $576.0 million

June 03, 2023

blank

Details:

Under the license agreement, Aclaris granted Sun Pharma exclusive rights under certain patents for the use of deuruxolitinib, Sun Pharma’s JAK inhibitor, or other isotopic forms of ruxolitinib, to treat alopecia areata (AA) or androgenetic alopecia (AGA).


Lead Product(s): Deuruxolitinib phosphate

Therapeutic Area: Dermatology Brand Name: CTP-543

Study Phase: Phase IIIProduct Type: Other Small Molecule

Sponsor: Sun Pharmaceutical Industries Limited

Deal Size: Undisclosed Upfront Cash: $15.0 million

Deal Type: Licensing Agreement May 12, 2023

blank

04

Hospitalar
Not Confirmed
Hospitalar
Not Confirmed

Lead Product(s) : Deuruxolitinib phosphate

Therapeutic Area : Dermatology

Highest Development Status : Phase III

Partner/Sponsor/Collaborator : Sun Pharmaceutical Industries Limited

Deal Size : Undisclosed

Deal Type : Licensing Agreement

Details : Under the license agreement, Aclaris granted Sun Pharma exclusive rights under certain patents for the use of deuruxolitinib, Sun Pharma’s JAK inhibitor, or other isotopic forms of ruxolitinib, to treat alopecia areata (AA) or androgenetic alopecia (AG...

Product Name : CTP-543

Product Type : Other Small Molecule

Upfront Cash : $15.0 million

May 12, 2023

blank

Details:

CTP-543 (deuruxolitinib) is an investigational oral selective inhibitor of Janus kinases JAK1 and JAK2. It has received breakthrough Therapy Designation from FDA for the Treatment of Alopecia Areata


Lead Product(s): Deuruxolitinib phosphate

Therapeutic Area: Dermatology Brand Name: CTP-543

Study Phase: Phase IIIProduct Type: Other Small Molecule

Sponsor: Inapplicable

Deal Size: Inapplicable Upfront Cash: Inapplicable

Deal Type: Inapplicable February 15, 2023

blank

05

Hospitalar
Not Confirmed
Hospitalar
Not Confirmed

Details : CTP-543 (deuruxolitinib) is an investigational oral selective inhibitor of Janus kinases JAK1 and JAK2. It has received breakthrough Therapy Designation from FDA for the Treatment of Alopecia Areata

Product Name : CTP-543

Product Type : Other Small Molecule

Upfront Cash : Inapplicable

February 15, 2023

blank

Details:

Concert has an extensive patent portfolio, including its lead product candidate CTP‑543 (deuruxolitinib) – an oral inhibitor of Janus kinases JAK1 and JAK2 for the treatment of Alopecia Areata, an autoimmune dermatological disease – which is in late-stage development.


Lead Product(s): Deuruxolitinib phosphate

Therapeutic Area: Dermatology Brand Name: CTP-543

Study Phase: Phase IIIProduct Type: Other Small Molecule

Sponsor: Sun Pharmaceutical Industries Limited

Deal Size: $576.0 million Upfront Cash: $576.0 million

Deal Type: Acquisition January 19, 2023

blank

06

Hospitalar
Not Confirmed
Hospitalar
Not Confirmed

Lead Product(s) : Deuruxolitinib phosphate

Therapeutic Area : Dermatology

Highest Development Status : Phase III

Partner/Sponsor/Collaborator : Sun Pharmaceutical Industries Limited

Deal Size : $576.0 million

Deal Type : Acquisition

Details : Concert has an extensive patent portfolio, including its lead product candidate CTP‑543 (deuruxolitinib) – an oral inhibitor of Janus kinases JAK1 and JAK2 for the treatment of Alopecia Areata, an autoimmune dermatological disease – which is in lat...

Product Name : CTP-543

Product Type : Other Small Molecule

Upfront Cash : $576.0 million

January 19, 2023

blank

Details:

Deuruxolitinib (CTP-543) is an investigational oral selective inhibitor of Janus kinases JAK1 and JAK2. Deuruxolitinib was generally well-tolerated in THRIVE-AA1, consistent with its other Phase 2 and Phase 3 studies.


Lead Product(s): Deuruxolitinib phosphate

Therapeutic Area: Dermatology Brand Name: CTP-543

Study Phase: Phase IIIProduct Type: Other Small Molecule

Sponsor: Inapplicable

Deal Size: Inapplicable Upfront Cash: Inapplicable

Deal Type: Inapplicable November 21, 2022

blank

07

Hospitalar
Not Confirmed
Hospitalar
Not Confirmed

Details : Deuruxolitinib (CTP-543) is an investigational oral selective inhibitor of Janus kinases JAK1 and JAK2. Deuruxolitinib was generally well-tolerated in THRIVE-AA1, consistent with its other Phase 2 and Phase 3 studies.

Product Name : CTP-543

Product Type : Other Small Molecule

Upfront Cash : Inapplicable

November 21, 2022

blank

Details:

Terran plans to quickly accelerate the development of these compounds as important complements to a growing pipeline of both early-stage and late-stage therapeutics and technologies in the CNS space.


Lead Product(s): Deuruxolitinib phosphate

Therapeutic Area: Dermatology Brand Name: CTP-543

Study Phase: Phase IIIProduct Type: Other Small Molecule

Sponsor: Terran Biosciences

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Agreement November 03, 2022

blank

08

Hospitalar
Not Confirmed
Hospitalar
Not Confirmed

Details : Terran plans to quickly accelerate the development of these compounds as important complements to a growing pipeline of both early-stage and late-stage therapeutics and technologies in the CNS space.

Product Name : CTP-543

Product Type : Other Small Molecule

Upfront Cash : Undisclosed

November 03, 2022

blank

Details:

The presentation highlights THRIVE-AA1 study results evaluating Concert’s oral investigational medicine CTP-543 (deuruxolitinib) in adult patients with moderate to severe alopecia areata, an autoimmune disorder that results in patchy or complete scalp hair loss.


Lead Product(s): Deuruxolitinib phosphate

Therapeutic Area: Dermatology Brand Name: CTP-543

Study Phase: Phase IIIProduct Type: Other Small Molecule

Sponsor: Inapplicable

Deal Size: Inapplicable Upfront Cash: Inapplicable

Deal Type: Inapplicable October 09, 2022

blank

09

Hospitalar
Not Confirmed
Hospitalar
Not Confirmed

Details : The presentation highlights THRIVE-AA1 study results evaluating Concert’s oral investigational medicine CTP-543 (deuruxolitinib) in adult patients with moderate to severe alopecia areata, an autoimmune disorder that results in patchy or complete scalp ...

Product Name : CTP-543

Product Type : Other Small Molecule

Upfront Cash : Inapplicable

October 09, 2022

blank

Details:

CTP-543 (deuruxolitinib) is an investigational oral selective inhibitor of Janus kinases JAK1 and JAK2, for the treatment of adult patients with moderate to severe alopecia areata.


Lead Product(s): Deuruxolitinib phosphate

Therapeutic Area: Dermatology Brand Name: CTP-543

Study Phase: Phase IIIProduct Type: Other Small Molecule

Sponsor: Inapplicable

Deal Size: Inapplicable Upfront Cash: Inapplicable

Deal Type: Inapplicable August 22, 2022

blank

10

Hospitalar
Not Confirmed
Hospitalar
Not Confirmed

Details : CTP-543 (deuruxolitinib) is an investigational oral selective inhibitor of Janus kinases JAK1 and JAK2, for the treatment of adult patients with moderate to severe alopecia areata.

Product Name : CTP-543

Product Type : Other Small Molecule

Upfront Cash : Inapplicable

August 22, 2022

blank
click full view
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

FDA Orange Book

read-more
read-more

01

Hospitalar
Not Confirmed
arrow
arrow
Hospitalar
Not Confirmed

DEURUXOLITINIB PHOSPHATE

Brand Name : LEQSELVI

Dosage Form : TABLET;ORAL

Dosage Strength : EQ 8MG BASE

Approval Date : 2024-07-25

Application Number : 217900

RX/OTC/DISCN : RX

RLD : Yes

TE Code :

blank
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

Digital Content read-more

Create Content with PharmaCompass, ask us

DATA COMPILATION #PharmaFlow

read-more
read-more
FDA okays 50 new drugs in 2024; BMS’ Cobenfy, Lilly’s Kisunla lead pack of breakthrough therapies
In 2024, the biopharma industry continued to advance on its robust trajectory of innovation. Though the US Food and Drug Administration’s Center for Drug Evaluation and Research (CDER) and the Center for Biologics Evaluation and Research (CBER) approved fewer drugs, there was a significant increase in medical breakthroughs.While the CDER approved 50 new drugs in 2024, as compared to 55 in 2023, the CBER granted 14 biologics approvals in 2024, down from 20 in 2023.The European Medicines Agency (EMA) approved 34 new therapies, up from 32 in 2023, while Health Canada granted 28 approvals, down from 38 in 2023.The year saw long-awaited treatments being approved in areas such as schizophrenia and Alzheimer’s disease in the second half (H2) of 2024. In H1 2024, drugs to treat metabolic dysfunction-associated steatohepatitis (MASH) and chronic obstructive pulmonary disease (COPD) had been granted FDA approvals.As the year drew to a close, FDA began approving drugs at a feverish pace, with 29 of the CDER’s 50 approvals coming in H2.Like most years, the landscape of drug approvals was dominated by oncology, with 15 of the 50 drugs (30 percent) approved targeting various forms of cancer. This was followed by dermatology and non-malignant hematology, each accounting for 12 percent of approvals. Notably, small molecules continued to dominate the market, making up for 64 percent of the new drug approvals, while 32 percent were proteins, including monoclonal and bi-specific antibodies. View New Drug Approvals in 2024 with Estimated Sales (Free Excel Available)Karuna-BMS’ schizophrenia drug, Lilly’s Alzheimer’s med, Neurocrine’s Crenessity dominate list of pathbreaking approvals in H2Out of the 50 new drugs approved in 2024, CDER identified 24 (48 percent) as first-in-class, showcasing novel mechanisms of action. The most anticipated approval of 2024 was Karuna and Bristol Myers Squibb’s Cobenfy, a groundbreaking treatment for schizophrenia. This fixed-dose combination of xanomeline and trospium chloride represents the first novel mechanism of action in decades for this debilitating psychiatric condition. Analysts forecast peak annual sales of over US$ 3.3 billion for Cobenfy. Eli Lilly’s Alzheimer’s drug Kisunla (donanemab) became the third amyloid-targeting antibody to gain FDA approval. Unlike its predecessors, Kisunla offers a unique limited-duration treatment regimen, allowing patients to discontinue therapy once amyloid levels in the brain drop below a certain threshold. Priced at approximately US$ 32,000 per year, it is positioned as a cost-effective alternative to existing treatments. Analysts estimate peak sales of US$ 2.4 billion for Kisunla.Crenessity (crinecerfont), developed by Neurocrine Biosciences, became the first FDA-approved treatment in decades for classic congenital adrenal hyperplasia (genetic conditions that affect the adrenal glands). Similarly, Vertex’s triple combination therapy of deutivacaftor, tezacaftor & vanzacaftor (Alyftrek) for cystic fibrosis represents a significant advancement in genetic disease treatment. Analysts forecast peak sales exceeding US$ 8.3 billion, underscoring the therapy’s potential to transform patient care.Meanwhile, Bridgebio’s Attruby (acoramidis hydrochloride) emerged as a promising treatment for cardiac amyloidosis, a life-threatening condition. View New Drug Approvals in 2024 with Estimated Sales (Free Excel Available) Roche’s Itovebi, Checkpoint’s Unloxcyt clinch FDA approvals in H2 2024; forecast to achieve blockbuster statusThe dominance of cancer drug approvals reflects the ongoing focus on targeted therapies, immuno-oncology, and precision medicine to improve outcomes for patients with hard-to-treat cancers.Among the year’s notable FDA approvals was Genentech’s Itovebi (inavolisib), another targeted therapy that treats hormone receptor-positive (HR+), HER2-negative breast cancer. Itovebi is a PI3Kα inhibitor designed specifically for patients with PIK3CA mutations, a common driver of resistance to endocrine therapy in breast cancer. It demonstrated a more tolerable safety profile. Roche projects Itovebi’s peak (annual) sales to reach CHF 2 billion (US$ 2.3 billion).Checkpoint Therapeutics’ Unloxcyt (cosibelimab) joined the crowded checkpoint inhibitor market as the eleventh PD-1/PD-L1-targeting monoclonal antibody approved by the FDA. It was granted approval for cutaneous squamous cell carcinoma (cSCC), an aggressive form of skin cancer with high recurrence rates. As compared to other checkpoint inhibitors, like Keytruda (pembrolizumab) and Opdivo (nivolumab), Unloxcyt is likely to offer an advantage in immune activation.FDA also approved Astellas’ Vyloy (zolbetuximab), a first-in-class monoclonal antibody for metastatic gastric and gastroesophageal junction (GEJ) adenocarcinoma. Analysts forecast peak sales of approximately US$ 850 million for Vyloy.Syndax Pharmaceuticals’ Revuforj (revumenib) was approved by FDA to treat a type of acute leukemia in both adults and children. This approval introduces a novel class of medications known as menin inhibitors. These agents are currently in clinical development for the treatment of genetically defined subsets of acute leukemia. These inhibitors function by preventing the activation of cancer growth-related proteins. View New Drug Approvals in 2024 with Estimated Sales (Free Excel Available) Potential blockbusters Lilly’s Ebglyss, Galderma’s Nemluvio lead advances in dermatologyEli Lilly’s Ebglyss (lebrikizumab) garnered significant attention. Approved by FDA for moderate-to-severe atopic dermatitis, this monoclonal antibody introduces a less burdensome dosing regimen compared to its competitors, with maintenance therapy required only once a month. This feature positions it as a potential contender to Dupixent (dupilumab), a market leader in atopic dermatitis. Ebglyss sales are forecast to reach US$ 1.9 billion by 2030.Galderma’s Nemluvio (nemolizumab) secured FDA approval for two indications in 2024 — prurigo nodularis (a chronic disorder of the skin) and moderate-to-severe atopic dermatitis in patients aged 12 years and older. As the first humanized IgG2 monoclonal antibody targeting the IL-31 receptor, Nemluvio directly inhibits the key driver of itch and inflammation in both these conditions. With its unique mechanism and broad dermatology potential, analysts forecast peak sales of approximately US$ 1.66 billion. Ebglyss and Nemluvio underscore the growing importance of biologics in dermatological care.Botanix Pharmaceuticals also made strides in dermatology by clinching an FDA approval for Sofdra (sofpironium) in June. The drug has been okayed for the treatment of primary axillary hyperhidrosis, a condition characterized by excessive sweating.Ascendis Pharma’s Yorvipath (palopegteriparatide), a therapy approved by FDA to treat hypoparathyroidism, is forecast to achieve blockbuster sales of US$ 1.8 billion by 2030, highlighting its potential to transform endocrine care. View New Drug Approvals in 2024 with Estimated Sales (Free Excel Available) Our viewOverall, 2024 was defined by its breakthrough drug approvals. The year also saw significant reduction in complete response letters (CRLs) — they dropped from 43 in 2023 to just 29 in 2024. This suggests improved industry preparedness and alignment with regulatory expectations.The new year began with the approval of Datroway (datopotamab deruxtecan) from AstraZeneca and Daiichi Sankyo, marking a significant advancement in oncology. Several other promising new drugs are coming up for FDA approval this year, such as J&J’s nipocalimab, Vertex Pharmaceuticals’ suzetrigine, Elevar Therapeutics’ rivoceranib/camrelizumab, Sanofi’s fitusiran and GSK’s gepotidacin. Hopefully, the momentum of breakthrough approvals will continue through 2025, political headwinds in the US notwithstanding. 

Impressions: 10566

https://www.pharmacompass.com/radio-compass-blog/fda-okays-50-new-drugs-in-2024-bms-cobenfy-lilly-s-kisunla-lead-pack-of-breakthrough-therapies

#PharmaFlow by PHARMACOMPASS
30 Jan 2025

NEWS #PharmaBuzz

read-more
read-more

Patents & EXCLUSIVITIES

Check the patents & exclusivity for this product

US Patents

read-more
read-more

01

arrow
Hospitalar
Not Confirmed
arrow
Hospitalar
Not Confirmed

DEURUXOLITINIB PHOSPHATE

US Patent Number : 12247034

Drug Substance Claim : Y

Drug Product Claim : Y

Application Number : 217900

Patent Use Code :

Delist Requested :

Patent Use Description :

Patent Expiration Date : 2044-05-10

blank

02

arrow
Hospitalar
Not Confirmed
arrow
Hospitalar
Not Confirmed

DEURUXOLITINIB PHOSPHATE

US Patent Number : 11919907

Drug Substance Claim :

Drug Product Claim : Y

Application Number : 217900

Patent Use Code : U-3976

Delist Requested :

Patent Use Description :

Patent Expiration Date : 2041-05-21

blank

03

arrow
Hospitalar
Not Confirmed
arrow
Hospitalar
Not Confirmed

DEURUXOLITINIB PHOSPHATE

US Patent Number : 10561659

Drug Substance Claim :

Drug Product Claim :

Application Number : 217900

Patent Use Code : U-3976

Delist Requested :

Patent Use Description :

Patent Expiration Date : 2037-05-04

blank

04

arrow
Hospitalar
Not Confirmed
arrow
Hospitalar
Not Confirmed

DEURUXOLITINIB PHOSPHATE

US Patent Number : 12076323

Drug Substance Claim :

Drug Product Claim :

Application Number : 217900

Patent Use Code : U-3976

Delist Requested :

Patent Use Description :

Patent Expiration Date : 2037-05-04

blank
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

ABOUT THIS PAGE

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty